San Diego drugmaker ACADIA Pharmaceuticals Inc. has appointed Todd Young as executive vice president and chief financial officer.
Young comes to ACADIA from Baxalta Inc. (acquired by Shire earlier this year for $32 billion), where he served as senior vice president and treasurer. Young played an integral role in creating the initial capital structure for Baxalta, according to an ACADIA news release. Baxalta brought in $6 billion in annual revenue before its acquisition.
Before Baxalta, Young worked at Baxter International Inc. for 14 years, in which he held several leadership roles.
As the finance leader for Baxter’s international operations, Young led a team of 900 finance members and helped drive results for the company’s $8 billion international commercial operations.
“Todd is a seasoned leader with significant financial and operational experience in the biopharmaceutical industry,” said Steve Davis, president and CEO of ACADIA, in a statement. “His proven finance and leadership skills will be key as we bring Nuplazid (pimavanserin) to patients in need, seek to maximize the significant opportunities ahead for pimavanserin, and deliver on our vision of building a leading CNS company.”
Earlier this year, ACADIA got FDA approval of its antipsychotic drug Nuplazid.